Myelodysplastic-Myeloproliferative Diseases clinical trials

The registry lists 200 studies for Myelodysplastic-Myeloproliferative Diseases across more than 10 countries. 21 are recruiting or about to start. 6 of them are mainly about Myelodysplastic-Myeloproliferative Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its 3 narrower conditions too, such as Leukemia, Myelomonocytic, Chronic: 692 studies, 92 open.

Get an email when these change. Save the Myelodysplastic-Myeloproliferative Diseases studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 126
Terminated: 30
Recruiting: 19
Active, not recruiting: 8
Status unknown: 8
Withdrawn: 7

Phase

Phase 2: 98
Phase 1: 60
Phase 3: 17
Early Phase 1: 1

Where

United States: 176
Canada: 12
France: 7
Germany: 7
Italy: 7
United Kingdom: 7

Who runs them

Fred Hutchinson Cancer Center (22) · Case Comprehensive Cancer Center (12) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (12) · M.D. Anderson Cancer Center (10) · City of Hope Medical Center (10) · Memorial Sloan Kettering Cancer Center (9) · National Cancer Institute (NCI) (8) · OHSU Knight Cancer Institute (7)

What is being tested here

Drugs under test in Myelodysplastic-Myeloproliferative Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Ruxolitinib	2	0	4
Cyclophosphamide	1	1	27
Busulfan	1	1	21
Melphalan	1	1	9
Decitabine	1	1	5
Azacitidine	1	0	4
Venetoclax	1	0	3
Clofarabine	1	0	3
Rituximab	1	0	3
Edetic Acid	1	0	2

Drug classes tested here Antimetabolites 3 open · Tyrosine kinase inhibitors (TKIs) 3 open · JAK inhibitors 2 open · Alkylating agents 1 open · Calcineurin inhibitors 13

Coming up

0phase 3 studies under way

12studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Dec 2026Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. · Newave Pharmaceutical Inc
Jan 2027Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes · M.D. Anderson Cancer Center
Mar 2027Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant · Omar Aljitawi
Apr 2027Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia · University of Manitoba
Apr 2027Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy · M.D. Anderson Cancer Center
May 2027Personalized NK Cell Therapy in CBT · M.D. Anderson Cancer Center
Jun 2027Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms · Mayo Clinic
Aug 2027Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm · National Cancer Institute (NCI)
Sep 2027A Telehealth Advance Care Planning Intervention · University of Rochester
Oct 2027Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia · Uma Borate

Who these studies take

Of the 19 Myelodysplastic-Myeloproliferative Diseases studies recruiting now, 14 (74%) set no upper age limit and 2 (11%) stop at 75 or younger. 4 (21%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 19
Age	Women	Men
10	2 (11%)	2 (11%)
18	17 (89%)	17 (89%)
30	17 (89%)	17 (89%)
40	17 (89%)	17 (89%)
50	17 (89%)	17 (89%)
65	19 (100%)	19 (100%)
75	19 (100%)	19 (100%)
85	16 (84%)	16 (84%)

Across all 200 studies, recruiting or not: 37% stop at 75 or younger and 26% at 65; 40% take children; 0% are for women only and 1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Myelodysplastic-Myeloproliferative Diseases studies take

Of 20 phase 2 interventional studies under Myelodysplastic-Myeloproliferative Diseases, half reached primary completion within 86 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 2	86 mo64–141 · 20 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 200. Browse all 200 → or search them.